Posts Tagged ‘studies’

More Hope for Melanoma Patients in a Year of Milestones

Wednesday, August 24th, 2011

Treatment options for melanoma have advanced in the past year with heartening results.  As we wrote in March 2011, the drug Yervoy (ipilimumab or “ipi”) appears to be successful for a small group of patients with inoperable, metastatic melanoma in extending survival.  In fact, WebMD says that “Yervoy … is the first drug ever shown to help late-stage melanoma patients live longer.”

Now, there’s more news to be hopeful about on the pharma front with potentially greater results: The FDA has also given the go-ahead to a drug called ZELBORAF (vemurafenib, pronounced vem-yoo-RAF-en-ib).   A comprehensive overview by ABC News offers a clear explanation of how Zelboraf attacks a genetic mutation (known as BRAF V600E) which is found in about half of melanoma patients, inhibiting the disease’s ability to spread.

We now have the capability to analyze a patient’s melanoma tumor for the genetic mutation BRAF and use the targeted treatment Zelboraf to attack the tumor, shrink it and stop the progression of this deadly disease,” said Dr. Anna Pavlick, director of the NYU Melanoma Program at the NYU Cancer Institute, who has been involved in clinical trials for Zelboraf. …Zelboraf shuts down the abnormal signals of the tumor cells that are caused by the genetic mutation and stops the cells from dividing, without affecting healthy cells.

At the same time, the FDA approved a genetic test to determine if patients carry the mutation since only those with the abnormal “BRAF” gene can take Zelboraf.  Interestingly, since the same genetic mutation is found in those with other forms of cancer, there may be future help from this drug beyond skin cancer and is now, for example, being tested on thyroid cancer patients.

This is the fastest the FDA has ever approved a drug to come to market – in just five years.  And even better: Zelboraf, which is a first-in-class drug, is anticipated to be available in the next two weeks.

There are differences between Yervoy and Zelboraf.   As described in the coverage by the SF Chronicle,

Yervoy was found to extend patients’ lives, an improvement over many current treatments. However, the drug works for less than 20 percent of patients, and doctors say they can’t predict which patients will find it most effective.

Zelboraf was clinically effective in 50 percent of patients [with the] specific genetic mutation … Most of the therapies for melanoma work for less than 20 percent of patients, and some fall into single digits.

Neither Zelboraf nor Yervoy cure melanoma.  And as a patient who had great success in a clinical trial for the new drug said, “there’s nothing that says this medication will help you forever.”  But these drugs bring hope for a longer life, and as new therapies come along the melanoma pipeline, there is reason to be optimistic.

Share

Women and Melanoma

Sunday, July 10th, 2011

There were two interesting studies out in the past several weeks regarding women and the risk of Melanoma, both of which were reported in the Journal of Clinical Oncology and are sort of “the good news and the not quite as good, but interesting, news.*”

First, as stated by MedPage Today,

“If you have to have malignant melanoma, be a woman – your chances are better.”

While it’s considered preliminary data, the article share that “women exhibited a consistent independent advantage in melanoma progression, metastasis, and survival across all stages which was independent of hormonal status.”

That means the results were the same, regardless of age.  The challenge is that we still don’t know WHY women survive melanoma or it progresses less quickly than in men. Even the speculation that it was behavioral was ruled out — such as men avoiding the doctor more than women — and is seen as something biological.  But what?:

It’s…not an obvious effect of changes in hormone levels driven by menopause. Women 45 or younger had similar rates of progression-free survival as women 64 and older. But there could be other hormonal factors, differences in vitamin D metabolism, or variation by sex in how people handle reactive oxygen species and oxidative stress, [Arjen Joosse, MD, of Erasmus University Medical center in Rotterdam, the Netherlands] speculated.

Even such a factor as obesity might play a role, since adipose tissue releases hormones, he said.

Indeed, the key question is no longer if the observation is true, but what’s causing it,

Vitamin D supplementation at a relatively low dose plus calcium did not reduce the overall incidence of NMSC or melanoma. However, in women with history of NMSC, CaD supplementation reduced melanoma risk, suggesting a potential role for calcium and vitamin D supplements in this high-risk group. Results from this post hoc subgroup analysis should be interpreted with caution but warrant additional investigation.

That leads us to the next report that just came out, and as reported by MedScape Today:

Calcium plus vitamin D supplementation did not reduce the overall incidence of nonmelanoma skin cancer (NMSC) or melanoma in postmenopausal women in the Women’s Health Initiative (WHI), researchers say.

However, the placebo-controlled study found that, in women with history of NMSC, calcium plus vitamin D supplementation reduced subsequent melanoma risk, suggesting a potential role for the supplements in this high-risk subgroup, said the authors, led by Jean Tang, MD, PhD, from Stanford University in California.

So, while we don’t know why women do better in battling melanoma, and we know that Calcium and Vitamin D seem to be ruled out as a factor in preventing the disease, there DOES seem to be some evidence that the supplements may hold melanoma at bay a bit in women who have had NON-melanoma skin cancers before.

The takeaway continues to be, as with our other posts on studies and treatment news, that we are continuing to gain ground and promising results are coming in.  But, we must continue the research and continue down the path a ways to reach a cure.

*Please remember, we share information on Melanoma Updates that we found interesting, inspirational, or thought-provoking.   Any science or clinical study news you read here or elsewhere should be reviewed with your doctor.

Share

There’s an App – and a list – for that Sunscreen

Monday, June 6th, 2011

Note:  Since we posted the below entry, good news: the FDA has now announced their new guidelines which will include mandatory labeling by the summer of 2012.  Here’s an excellent overview from ABC:

In the meantime, please remember to review your choices, and keep applying that sunscreen!

The Environmental Working Group’s guide to effective and less-toxic or non-toxic sunscreens is out again with additional options on this 2011 version. This comprehensive list, and associated articles, does an excellent job of explaining the challenges with both the FDA’s progress in setting standards for sun-protection products…and consumers’ understanding of the elements that go into that sunscreen — good or bad.

Even since we shared their 2010 list last May, more outcry has been heard about a common ingredient in many mainstream sunscreens, that is a derivative of Vitamin A: Retinyl palmitate.  In fact, in June of last year, Senator Chuck Schumer called on the FDA to investigate it, as mentioned in this release from his office:

Retinyl palmitate is an ingredient found in most of the 500 most popular sunscreen products. Scientists at both the NCTR and the NTP have been working diligently over the last decade at the FDA’s request in order to determine whether this Vitamin A derivative, retinyl palmitate, is safe to use in sunscreen products. In one study, tumors and lesions developed up to 21 percent faster in lab animals coated in retinyl palmitate-laced cream than animals treated with a cream that did not contain RP. While these studies have been completed for almost a year now, the FDA has not issued an assessment of ruling on either of them….

Schumer added, “Millions of Americans use sunscreen to keep themselves and their families protected from the dangers of too much sun. If the product they are using is doing more harm than good, they have a right to know.”

Of course, there is NO safe way to TRY to tan, just as the American Academy of Dermatology says. But in tan PREVENTION, there are things to consider.  Here’s something from a section on their Website about sunscreen, that you might not have known:

Q: When should sunscreen be used?
A: Sunscreen should be applied every day to exposed skin, and not just if you are going to be in the sun. UVB rays cannot penetrate glass windows, but UVA rays can, leaving you prone to these damaging effects if unprotected.

For days when you are going to be indoors, apply sunscreen on the areas not covered by clothing, such as the face and hands. Sunscreens can be applied under makeup, or alternatively, there are many cosmetic products available that contain sunscreens for daily use. Sun protection is the principal means of preventing premature aging and skin cancer. It’s never too late to protect yourself from the sun and minimize your future risk of skin cancer.

Don’t reserve the use of sunscreen only for sunny days. Even on a cloudy day, up to 80 percent of the sun’s ultraviolet rays can pass through the clouds. In addition, sand reflects 25 percent of the sun’s rays and snow reflects 80 percent of the sun’s rays.

So, as the inquiry continues, we, again, are of the belief that smart skin cancer prevention tactics start with covering up and include generous use of sunscreen. Of those, perhaps making a more natural choice of mineral (titanium dioxide, for example) vs non-mineral protection is a better option.  The  introductory paragraph to the Environmental Working Group’s guide says it all:

The best sunscreen is a hat and a shirt. No chemicals to absorb through the skin, no questions about whether they work. But when you can’t get away from exposing your skin to the sun, use EWG’s top-rated sunscreens to provide broad-spectrum (UVA and UVB-sunburn) protection with fewer hazardous chemicals that penetrate the skin. Sunscreen and sunblock makers are awaiting FDA approval for a wider selection of UVA-blocking chemicals. In the meantime, all [the Guide's] top-rated products contain either zinc or titanium minerals to help cut UVA exposures for sunscreen users.

PS: And now, yes, “there’s an app for that.”  EWG Sunscreen Buyer's Guide for iPhone, iPod touch, and iPad on the iTunes App Store_1307304366893The EWG Sunscreen guide reviews some 1700 products, so keeping them straight at the point of purchase will be easier for iPhone owners now.  Check it out in iTunes app store, for free.   

Share

If you must tan…

Friday, April 15th, 2011

There is still a feeling by many that tan-looking skin is preferable to pale.  We’re still working to buck this perception Rome wasn’t built in a day. So, for those who still want the glow but have at least gotten the message that they should do it without the sun, here are some suggestions by NBC’s Today Show  style editor, Bobbie Thomas on the best of sunless tanners.

Note: this is not an endorsement of any particular product…just an endorsement of getting the look you want in a safer way:

1. First up, cult favorite “Big Bronzer” by Cargo Cosmetics. The jumbo oversized palette will instantlBuzz from Bobbie Thomas_1302394347737y warm up your face or body. With just a hint of shimmer, you can quickly apply a little or a lot for a natural looking glow.
2. For an even easy-to-apply application simply swipe on a little color… Kate Somerville’s Tanning Towelettes are paraben-free, streak-free and mess-free, while Dr. Denese’s Glow Younger Self-Tanning Gloves will do the same and offer anti-aging benefits.
3. New on the bronzing scene is Temptu’s Summer Skin 3 Step Air Pod system–perfect for die-hard spray tan fans who want to give it a go at home.
4. Last but not least, if you want a faux glow without the long-term commitment, L’Oreal and St. Tropez both offer great “1 Day” options that easily wash away with soap & water.

PS:  The timing has never been better for encouraging your teen to try sunless tanners. According to the American Academy of Dermatology, which officially opposes indoor tanning and supports a ban on indoor tanning for non-medical purposes, most tanning salon patrons are white females in their teens and 20s.  And not coincidentally they also point out:

  • Melanoma is the second most common form of cancer for adolescents and young adults 15-29 years old.
  • Melanoma is increasing faster in females ages 15-29 than males in the same age group. The torso is the most common location for developing skin cancer which may be due to deliberate tanning.
  • Studies have demonstrated that exposure to UV radiation during indoor tanning can lead to skin aging, immune suppression, and eye damage, including cataracts and ocular melanoma.
  • So consider Bobbie’s sunless tanners recommendations or take those of the AADA and just say no to tans altogether.

    Share

    Green Light for Yervoy May Slow Melanoma in Its Tracks

    Monday, March 28th, 2011

    As we wrote about back in June, the most promising drug in the war on Melanoma, ipilimumab, was fast-tracked and finally approved as “Yervoy” for Bristol-Myers Squibb by the FDA last week.

    Ipi is an immune therapy drug: it tries to activate or stimulate the immune system to clear cancer cells. While ipi’s funny name has not improved much with a brand name like Yervoy, it is anything but laughable.  We have been challenged to make ANY progress with drug therapy and this new therapy is a welcome advance. With the usual current immuno-therapy treatments, such as interleukin, we haven’t been able to significantly extend the immune response to melanoma cells.  As described on WebMD:

    Yervoy appears to extend survival when used as a first-line treatment for inoperable stage III or stage IV melanoma, Bristol-Myers announced earlier this week. Details of the study will be reported at the June meeting of the American Society of Clinical Oncology.

    Yervoy is a biologic therapy. It’s a kind of man-made antibody (a monoclonal antibody) that blocks a crucial switch on immune cells called CTLA-4. Cancers use this switch to turn off the body’s anticancer immune responses.

    Most drugs like this come with possibly severe side effects, and Yervoy is no exception. The drug can provoke powerful autoimmune reactions in which the immune system attacks normal cells in the body. In clinical trials, nearly 13% of patients taking Yervoy had severe or fatal autoimmune reactions.

    Even with those caveats this does seem to be some light at the end of the tunnel:

    FDA approved the drug based on a Bristol Myers study of 676 people with advanced, inoperable melanoma who had already failed two other treatments, giving them a very short life expectancy. They were given one of three treatments: ipilimumab by itself, ipilimumab combined with another immune-stimulating treatment, or the immune-stimulating treatment alone.

    Average survival was 10 months with ipilimumab versus just more than six months for the others. But a very small group of patients survived longer than six years, suggesting that with more study the drug could be targeted to those who will respond the most.

    About 85 percent of patients had little response to the drug. Researchers say the response rate should improve as the drug is used earlier in the disease cycle.

    “I think the direction this is headed is toward intervening earlier, when patients’ immune systems are still intact, rather than waiting until they are so sick,” said Dr. Anna Pavlick, director of the New York University’s melanoma program. Pavlick, a spokeswoman for the Skin Cancer Foundation, helped conduct several early-stage trials of ipilimumab.

    Bristol-Myers Squibb expects to begin shipping YERVOY within weeks.

    Share

    Take Five so Melanoma Doesn’t Take a Life

    Saturday, February 12th, 2011

    Valentine’s Day is upon us once again with another a way to show your love, and show your skin!  According to the Skin Cancer Foundation couples with close bonds are about three times more likely to perform a mutual skin exam. Unofficial sources suggest those couples have more fun, too!  But kidding aside, we all need to find every opportunity to scrutinize our skin, from head to between the toes. Here’s how. add-molemap

    While dermatascopes and the analyses used at MoleSafe are the most effective in detecting skin cancers and Melanoma, being vigilant by starting with your own naked eye exam is important, too.  AND it’s important for doctors to mandate that as well.  Shockingly, only 59.6 percent of family practitioners and 56.4 percent of internists conduct regular full-body skin exams, compared to 81.3 percent of dermatologists. (We would like to know why it is not 100% of dermatologists, though.)

    According to a story in Bloomberg Businessweek last month,

    “The most common reasons for not performing this type of examination were patient embarrassment/reluctance, time constraints, and other patient illnesses.”

    About half of the internists and family practitioners cited time constraints as an impediment to conducting the naked eye exams.

    I find all those reasons unacceptable since taking five minutes is nothing compared to a diseases that takes lives.

    Our post in 2009 here on Melanoma Updates publicized the suggestion that not only should medical students be trained in naked eye exams no matter their ultimate specialization, but asking your doctor to keep an eye open while checking your lungs and seeing your back, or seeing your legs while checking your reflexes.

    So, show the love this year and start by checking yourself, check your mate, and check with your doctor.

    Share

    On Common Ground: Applying “Open Source” to Cure Melanoma

    Tuesday, January 18th, 2011

    Most doctors feel for their patients and we empathize with the challenges of their illness.  We work to the best of our experience and understanding to find cures, solutions, or sometimes just more comfort.  But when it comes to big challenges, such as advancing treatment options for diseases like Melanoma, sometimes empathy is not enough.  Sometimes what sparks the motivation to find solutions or cures is personal experience….

    That is what spurred e-commerce entrepreneur, Marty Tennenbaum.  While he’s not a doctor or even medical researcher, he does know his way around computers, and the value of “open source” as a route to developing solutions.  So, after surviving Melanoma in the late ’90s he begin applying his expertise to help move the needle on treatment solutions.

    Many scientists today work in relative isolation, left to follow blind alleys and duplicate existing research. Data are fragmented — trapped behind firewalls, locked up by contracts or lost in databases that can’t be accessed or integrated. Materials are hard to get — universities are overwhelmed with transfer requests that ought to be routine, while grant cycles pass and windows of opportunity close.

    Marty recognized that dilemma and his doing his part to use his tech know-how to bring about a tool to help solve that problem:  An app.

    Dr. Marty Tenenbaum, a survivor of melanoma, shows off his free Cancer Commons app

    Dr. Marty Tenenbaum, a survivor of melanoma, shows off his free Cancer Commons app

    Launching today (1/18/11), the “Cancer Commons” app will integrate existing data about melanomas, and cross reference promising experimental treatments.   Then, patients or doctors can in put patient-specific info on the progression of the disease including test results, such as specific genetic mutations.

    “From that information, the app tells patients what specific cancer “subtype” they have as determined by an expert panel. They also learn what drugs have shown the most promise in treating that specific form of the disease and where clinical trials are being conducted that could allow patients access to that treatment.”

    Marty explains that he’s just “trying to pull together all the pieces that are needed to do a real, rational attack on cancer.”

    …’The way to do that,’ he says, ‘is to pull people out of their individual labs, offices and hospitals to collaborate in a way not possible before the Web and mobile technologies made it easy to pool vast amounts of information.

    ‘How much of cancer could be turned into a manageable disease if we only knew what we knew?’”

    It’s a challenge to wrap our arms around the collected knowledge of thousands of researchers.  Groups like Health Commons and Open Science are taking a page from today’s socially networked world to tap that trust and are working to throw open the doors to the brain trust.  MoleSafe and Melanoma Updates applauds this approach, and gives Marty Tennenbaum and the collected participants pitching in a big Hat’s On Award to helping shine the light on the way to a cure for Melanoma and other cancers.

    Share

    Shining the light on Vitamin D

    Thursday, January 6th, 2011
    It’s pretty common knowledge by now that sun on human skin leads to the production of Vitamin D, which has been touted for reducing the risk of everything from Type 2 Diabetes to many cancers.  So, with science’s increased recommendations to avoid the sun and increase regular use of sunscreen there has been some concern that we would have a deficit of this nutrient. Not only is this concern unjustified, it is a slippery slope to rationalizing the “need” for a tan. For example, an article in Allure Magazine, which I wrote about recently, discussed the dangers of tanning.
    But one young woman, “Katie_k”, who posted a comment, had convinced herself that her tanning salon use was justified by the need for Vitamin D.    Here’s what I wrote to her in response:

    This article is important.   And to Katie_k who vowed to continue using tanning beds out of concern about low Vitamin D scares:   My answer? You’re wrong. The fact is, we can now check our  vitamin D level and take supplements should we be found to be deficient.  Skin cancer is nothing to be messed with. Exposing ourselves to a carcinogen like UV rays is never a good idea. Using a tanning bed is especially a bad one.

    I am concerned about the Katie_ks of the world. So here’s a reminder from a good summary article, to try again to allay fears about a lack of Vitamin D:

    “For most children, teens and adults, a daily dose of 400 international units (IUs) of the vitamin is sufficient, and 600 IUs are recommended. Seniors older than 70 should ideally receive 800 IUs of vitamin D a day, the panel determined. For babies younger than 1, the panel considered 400 IUs of vitamin D enough.

    Those levels are somewhat higher than the ones set in 1997, the last time a government panel examined vitamin D intake. But they are far below what many doctors and supplement advocates had been urging….

    Does that mean I should give up my vitamin D supplements?

    Maintaining a healthy level of vitamin D through diet alone has become much easier since manufacturers began fortifying foods with the nutrient. Fortified foods — including virtually all milk, many brands of orange juice, and some cheeses, yogurts, margarines and breakfast cereals — are now some of the richest dietary sources of vitamin D. High levels exist naturally in fatty fish such as tuna, salmon and mackerel, and it’s also present in egg yolks and beef liver….

    Indeed, the sun is a free, plentiful source of vitamin D. When the sun shines on human skin for at least five to 15 minutes, the body produces the nutrient. But with people spending more time indoors and using sunscreen to prevent skin cancer, this source has fallen on hard times. In fact, the panel didn’t even factor in vitamin D from sun exposure when it made its recommendations.

    Does that mean I should lay off the sunscreen?

    The sun can be a powerful manufacturer of the nutrient: In 15 minutes, a light-skinned person wearing a bathing suit outside in early July will produce 15,000 to 20,000 IUs of Vitamin D.

    The body stores excess vitamin D in fat, and some research suggests that it is released as needed. But there’s debate about how well that happens, so the panel members suggest that daily dosing of vitamin D is a better bet.

    Besides, even 15 minutes without sunscreen won’t fly with dermatologists. They warn that prolonged exposure to ultraviolet light – either from the sun or in a tanning booth – elevates a person’s risk of developing melanoma, the deadliest form of skin cancer. So, by all means, slather on that sunscreen.”

    Do read the whole story.  Here’s a link to that and another good story about Vitamin D.

    So, drink your fortified milk and toast to your good health.

    Share

    Deciphering Treatment News for Melanoma

    Tuesday, September 14th, 2010

    The past couple of months, some compelling new stories have circulated about promising Melanoma treatments. In June, you read about “ipi” – in the news and here on Melanoma Updates. And, this past month, more news touted early clinical trials with another targeted therapy drug, PLX4032. As always, we are cautiously optimistic, but to shed some light on two exciting, but still emerging options, I thought a basic overview might be helpful.

    So, what do these drugs do? Quite simply, one attacks a gene mutation found in about 50% of all melanoma patients. And one works to modulate the immune system.

    Ipi for Immunity

    Ipi is an immune therapy drug: it tries to activate or stimulate the immune system to clear cancer cells. With the usual current immuno-therapy treatments, such as interleukin, we haven’t been able to significantly extend the immune response to melanoma cells. But Ipi has been shown to extend that immune protection for longer and longer time spans, for the first time ever, leading to 2-year survival rates in around 56% of a certain group of patients (again, with advanced melanoma survival rates typically not extending past 10 months.) Ipi has been in advanced trials for years, and the very promising Phase III results spurred the recent media frenzy. As such, it is on the fast track for priority approval – perhaps as soon as the end of this year – and may become the first new melanoma drug approved in decades.

    Gene Mutation Therapy

    First, it’s important to know that about half of patients with metastatic melanoma have a mutation in a gene called BRAF. This is a gene that seems to program the “runaway cell division that is a hallmark of cancer.” When the impact of the BRAF gene mutation was established, scientists set to work to find a way to switch it off or slow down the programming to cells, and one of those ways may be an exciting new gene therapy drug, PLX4032 (no catchy name as of yet.) A remarkable 81% of cases showed marked and in many cases immediate improvement and reduction in tumor size and growth. Granted, the news came after just a small Phase I clinical trial, but there was such excitement about the results that in a rare move, the drug has skipped Phase II and is now being tested in longer term and wider scope Phase III trials.

    As reported in USA Today:

    No other drug has ever helped that high a percentage of patients with melanoma or any other solid tumor, says Paul Chapman, co-author of the study in today’s New England Journal of Medicine. The results are especially striking, he says, considering that only 10% to 20% of patients respond to standard treatments for melanoma, which don’t improve overall survival.

    USA Today also has a sidebar Q&A piece that does a nice job of summarizing the caution and optomisim surrounding PLX4032. They include a phone number for more information about it as well: 888-662-6728.

    A One-Two Punch?

    Since the back to back encouraging news broke for ipi and PLX4032, some are combining the two in other drug therapy trials. Here is a quote from the National Cancer Institute Bulletin this past week:

    In June, researchers announced that ipilimumab, a treatment that targets the immune system, helped patients with advanced melanoma live longer. Together, ipilimumab and PLX4032 have changed the landscape of melanoma research and raised the prospect that the new agents could be tested in combination or sequentially, said Dr. Claudio Dansky Ullmann, who oversees melanoma trials for the NCI Cancer Therapy Evaluation Program.

    "These studies have opened the doors to a lot of possibilities for treating metastatic melanoma,” said Dr. Dansky Ullmann. "We can now test many treatments that were not available or proven until recently. This area of research is taking off.”

    Share

    Melanoma News and Reviews – Ipi and “The Big C”

    Friday, August 20th, 2010

    Just watched the premiere of Showtime’s new hit, “The Big C,” in which Laura Linney plays a woman newly diagnosed with Stage Four Melanoma. The plot revolves around her decision to “carpe diem” and forgo traditional therapies to live out her anticipated remaining year joyfully and sometimes frivolously. As the show’s writer says,

    “in many ways, this series is not about cancer per se. It’s about living the life we want to live and not wasting our precious time!”

    “Seizing the day” can be a good prescription for any human being, and I encourage it wholeheartedly (though not as foolhardily, perhaps, as she does, when she knocks down her porch and shade tree to spontaneously add a swimming pool to her small front yard!) However, I would remind viewers that while the most serious and often most aggressive form of skin cancers, melanoma can be treatable and when caught early especially with proper screenings does not have to be a death sentence.

    Aside from that, it is good to see the disease brought to light. While there is not much apparent sidebar content or instructive information about melanoma on Showtime’s site, there is an alliance with the American Cancer Society that promises donations in exchange for viewing a clip of the show…a good approach to raise awareness of the show, for sure, but also for our passion: raising awareness about melanoma.

    View Big C trailer to have $1 Donated, thanks to Showtime and American Cancer Society

    View Big C trailer to have $1 Donated, thanks to Showtime and American Cancer Society

    And here’s a link to the Big C Facebook page in case you want to participate there (to be sent right to that page be sure you’re logged in on Facebook) and weigh in. Oddly, though, neither that Facebook page or the Showtime page for the show itself seem to provide any links to the More Birthdays Facebook page which they are supporting. That is a lost opportunity to drive more donations and align themselves deeper with the cause. Clearly, this is a “comedy that plays with dark and light tones.” And entertainment sells, but there is always more room for responsible education, even if via links from their site.

    In terms of Cathy’s life expectancy, as depicted on the show, it is, unfortunately fairly accurate: The typical survival rate for patients with metastatic melanoma is six to nine months. However, the new drug you may have read about here in June and elsewhere is continuing to show some promise in extended life expectancy, if slowly:

    Metastatic melanoma patients who took the drug demonstrated a median survival rate of 10 months, a 3.6 month improvement over those who did not take the medication.

    No one is laughing about the seriousness of melanoma. But we all must just keep trying to find the joy, if even through television escapes.

    Share